Cocrystal Pharma Appoints Biopharma Veteran James Sapirstein as New CEO
COCP sits 21% above its 52-week low of $0.859 on light trading volume (0.1× avg).
Summary
Cocrystal Pharma appointed James Sapirstein, a biopharma veteran with significant antiviral development and product launch experience, as its new CEO. This leadership change is crucial for the micro-cap company as it addresses a 'going concern' warning and seeks to advance its clinical pipeline.
Key Events · Executive and Board Changes · COCP
-
New CEO Appointed
James Sapirstein has been appointed Chief Executive Officer, effective immediately. He is also planned to be appointed to the Board of Directors.
-
Leadership Realignment
Former Co-Chief Executive Officers, Sam Lee and Jim Martin, will transition to President and Chief Scientific Officer, and Chief Financial Officer, respectively.
-
CEO's Extensive Experience
Mr. Sapirstein brings significant biopharma industry leadership, antiviral development experience, and a track record of 23 product launches and numerous business development transactions.
-
Strategic Timing Amidst Challenges
This leadership change occurs as the company faces a 'going concern' warning and an urgent need for capital, following a recent $150 million shelf registration filing.
Analysis · COCP · Life Sciences
Cocrystal Pharma, a company under a 'going concern' warning and actively seeking capital, has appointed James Sapirstein as its new Chief Executive Officer. Mr. Sapirstein brings extensive experience in biopharma leadership, antiviral development, and a track record of 23 product launches and numerous business development transactions. This leadership change is critical as the company navigates its financial challenges and aims to advance its clinical pipeline, particularly its norovirus drug candidate CDI-988, which recently received FDA Fast Track designation. His expertise could be instrumental in securing necessary funding and driving commercialization efforts.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.3% of the 1492 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COCP was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.5M. The 52-week trading range was $0.86 to $2.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.